Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo.

@article{Mohutsky2006GinkgoBE,
  title={Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo.},
  author={Michael A. Mohutsky and Gail D Anderson and John W. Miller and Gary W. Elmer},
  journal={American journal of therapeutics},
  year={2006},
  volume={13 1},
  pages={
          24-31
        }
}
Ginkgo biloba extract is one of the most widely used herbal products in the United States. However, bleeding episodes in patients taking Ginkgo biloba and warfarin have been documented. Therefore, in vitro and in vivo inhibition studies were done to ascertain the influence of ginkgo on CYP2C9, the P-450 isozyme responsible for the metabolism of the most potent warfarin enantiomer, (S)-warfarin. Ginkgo extract inhibited human liver microsomal CYP2C9 with an apparent Ki=14.8 microg/mL, and the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Ginkgo biloba Extract for Patients with Early Diabetic Nephropathy: A Systematic Review

  • Evidence-based complementary and alternative medicine : eCAM
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND